Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)

A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) Versus Surgically Targeted Radiation Therapy (STaRT) With Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors.

This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.

Study Overview

• Status: Recruiting
• Conditions: Brain Metastases
• Intervention / Treatment: Device: Gamma Tile-Surgically Targeted Radiation Therapy (STaRT); Radiation: Stereotactic Radiation Therapy

Detailed Description

GammaTile therapy results in improved clinical outcomes; however the data is a single site experience with a limited number of subjects, only 12 of which were patients with metastatic brain tumors. The primary objective of this randomized, controlled trial is to compare the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care. The data collected in this trial design will allow for a direct comparisons of a variety of outcomes including local control, overall survival, functional status, quality of life, neurocognitive status and safety in the target population. In order to support direct comparisons, subjects will be randomized to the two equally sized arms (1:1) based on the following stratification factors; age (<60 and ≥60), duration of extracranial disease control (≤3 months vs >3 months), number of metastases (one vs multiple), histology (lung and radiation resistant), and the maximal diameter of the index lesion (≤3 cm and >3 cm) and use of prior or current immunotherapy (yes vs no).

An index lesion meeting the criteria of ≥ 2.5cm in maximum diameter and appropriate for gross total resection (GTR), will be identified and up to three other non-resectable lesions in a patient will be allowed. After resection of the index lesion, the surgical bed will be treated with adjunct radiation (either GT or SRT) thereby following the standard of care guideline. (NCCN Guidelines, 2019). Additional, unresected metastatic lesions will be treated with stereotactic radiosurgery alone, which also adheres to standard of care guidelines (NCCN Guidelines, 2019).

GammaTile is an FDA-cleared means of rapid dose delivery of radiation therapy directly to the tumor bed with predictable dosimetry at the immediate time of re-resection, and a intense but localized radiation treatment may confer a reduced risk for radiation necrosis compared to other therapies. It is typically easly placed with minimal additional operative time and limited staff radiation exposure.

Given these benefits, the rationale for conducting this randomized control comparison study is to generate additional data, to further support the use of this new FDA-cleared method of delivering radiation therapy in the setting of newly diagnosed brain metastases.

• Study Type: Interventional
• Enrollment (Estimated): 180
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Michael A. Garcia, MD, MS; Phone Number: (833) 662-0044; Email: mgarcia@gtmedtech.com
• Study Contact Backup: Name: Sita Patel GT Medical Technologies, PhD, PharmD; Phone Number: (833)662-0044; Email: spatel@gtmedtech.com

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85027
      • Recruiting
      • HonorHealth Research Institute
      • Contact: John Wanebo, MD
      • Principal Investigator: John Wanebo, MD
  • Arkansas
    • Little Rock, Arkansas, United States, 72205
      • Recruiting
      • University of Arkansas Medical Center
      • Contact: Analiz Rodriguez, MD, PhD; Phone Number: 501-296-1138
      • Principal Investigator: Fen Xia, M.D, Ph.D
  • California
    • Los Angeles, California, United States, 90048
      • Recruiting
      • Cedars-Sinai Medical Center
      • Contact: Jeremy Rudnick, MD; Email: cancer.trial.info@cshs.org
    • Los Angeles, California, United States, 90033
      • Withdrawn
      • Keck Hospital of USC
  • Florida
    • Orange Park, Florida, United States, 32073
      • Recruiting
      • HCA Florida First Coast Neurology- Orange Park
      • Contact: Michael Horowitz, MD; Phone Number: 904-272-9981
      • Principal Investigator: Michael Horowitz, MD
    • Orlando, Florida, United States, 32804
      • Recruiting
      • Advent Health Orlando
      • Contact: Jack Ramsberger; Phone Number: 407-303-2090
      • Principal Investigator: Imran Mohiuddin, MD
  • Georgia
    • Atlanta, Georgia, United States, 30309
      • Active, not recruiting
      • Piedmont Hospital
    • Atlanta, Georgia, United States, 30322
      • Recruiting
      • Winship Cancer Institute of Emory University
      • Contact: Kimberly Bojanowski; Phone Number: 404-778-7215
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Recruiting
      • Indiana University, IU Health Methodist Hospital
      • Contact: Mitesh Shah, MD
  • Kansas
    • Kansas City, Kansas, United States, 66016
      • Recruiting
      • The University of Kansas Cancer Center
      • Contact: Paul Camarata; Phone Number: 913-588-5575
  • Michigan
    • Detroit, Michigan, United States, 48202
      • Recruiting
      • Henry Ford Health
      • Principal Investigator: Adam Robin, MD
      • Contact: Raid Faddah, MBBS, CCRP; Phone Number: 313-916-2723
  • Minnesota
    • Minneapolis, Minnesota, United States, 55414
      • Recruiting
      • University of Minnesota
      • Contact: Clark Chen, MD
    • Minneapolis, Minnesota, United States, 55407
      • Recruiting
      • Abbott Northwestern Hospital
      • Principal Investigator: Andrea Wasilewski, MD
      • Contact: Jennifer Murwin; Email: jennifer.murwin@allina.com
  • Missouri
    • Columbia, Missouri, United States, 65212
      • Recruiting
      • Ellis Fischel Cancer Center at University of Missouri
      • Principal Investigator: Gregory Biedermann, MD
      • Contact: Karissa Bryant, RN, BSN; Phone Number: 573-884-7482; Email: magruderka@health.missouri.edu
  • New York
    • Albany, New York, United States, 12208
      • Recruiting
      • Albany Medical Center
      • Principal Investigator: Alexandra Paul, MD
      • Contact: Alexandra Paul, MD; Phone Number: 518-262-5088; Email: neurosurgery@amc.edu
    • New York, New York, United States, 10065
      • Recruiting
      • Memorial Sloan Kettering
      • Contact: Brandon Imber, MD; Phone Number: 631-636-0677
      • Principal Investigator: Brandon Imber, MD
      • Sub-Investigator: Nelson Moss, MD
    • Westchester, New York, United States, 10595
      • Recruiting
      • Westchester Medical Center
      • Contact: Simon Hanft, MD; Phone Number: 914-493-2363
      • Principal Investigator: Simon Hanft, MD
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • Recruiting
      • University of North Carolina Health
      • Contact: Flora Danquah; Phone Number: 919-966-4432; Email: flodanq@email.unc.edu
      • Principal Investigator: Colette Shen, MD
    • Greenville, North Carolina, United States, 27834
      • Recruiting
      • ECU Health
      • Contact: Stuart Lee, MD; Phone Number: 252-847-1550
  • Ohio
    • Cincinnati, Ohio, United States, 45209
      • Recruiting
      • Mayfield Brain and Spine
      • Contact: Vincent DiNapoli, MD; Phone Number: 513-569-5369
      • Contact: Lauren Murphy; Phone Number: 513-484-0404
      • Principal Investigator: Vincent DiNapoli, MD
  • Texas
    • Dallas, Texas, United States, 75235
      • Recruiting
      • UT Southwestern, Simmons Cancer Center
      • Contact: Anita Harris; Email: Anita.Harris@UTSouthwestern.edu
      • Principal Investigator: Toral R Patel, MD
      • Contact: Phone Number: 214.645.1853
    • Houston, Texas, United States, 77030
      • Recruiting
      • The University of Texas M. D. Anderson Cancer Center
      • Contact: Jeffrey Weinberg, MD; Phone Number: 713-792-2400; Email: jweinberg@mdanderson.org
  • Washington
    • Seattle, Washington, United States, 98101
      • Recruiting
      • Virginia Mason
      • Principal Investigator: Huong Pham, MD
      • Contact: Jamie Leitzinger; Phone Number: 206-287-6278

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patients aged 18 years old and above. Eligibility is restricted to this age group given that the battery of neurocognitive tests utilized in this protocol are not developed or validated for use in a younger population.
2. One to four newly diagnosed brain metastases, identified on the screening MRI, from an extracranial primary tumor.
3. One lesion, designated the index lesion, is planned for surgical resection and is to be between 2.5 cm and 5.0 cm on the screening MRI. Index lesions ≥2.0 cm but <2.5 cm are also eligible if surgery is deemed clinically necessary and appropriate for an attempted gross total resection by the neurosurgeon.
4. Non-index lesions must measure < 4.0 cm in maximal extent on the screening MRI brain scan. The unresected lesions will be treated with SRT as outlined in the treatment section of the concept.
5. All metastases must be located > 5 mm from the optic chiasm and outside the brainstem. Dural based metastasis are eligible.
6. Previous and/or concurrent treatment with investigational or FDA approved systemic therapies (e.g., chemotherapy, targeted therapeutics, immunotherapy) is permitted and must follow protocol guidelines as follows: Systemic therapy is allowed a minimum of one week from last systemic therapy cycle to surgical resection, and one week after surgical resection to allow a minimum of one week before starting/resuming systemic therapy, depending on the specific systemic agent(s), as recommended by medical/neuro-oncology. Systemic therapy is not allowed 1 day before SRT, the same day as the SRT, or 1 day after the completion of the SRT or longer, depending on the specific systemic agent(s), as recommended by medical/neuro-oncology. Agents that are delivered by implant or depot injections (such as hormonal therapies) are excluded from these restrictions.
7. KPS score of ≥70.
8. Stable systemic disease or reasonable systemic treatment options predicting a life expectancy of ≥6 months.
9. Ability to complete an MRI of the head with contrast
10. Adequate renal and hepatic function to undergo surgery, in investigators opinion.
11. For women of childbearing potential only, a negative urine or serum pregnancy test done <7 days prior to randomization is required. Women must be willing to notify investigator immediately if they become pregnant at any time during the trial period.
12. Men and women of childbearing potential must be willing to employ adequate contraception throughout the study and for men for up to 3 months after completing treatment.
13. Subjects must be fluent in English or Spanish language. English speaking subjects will complete Neurocognitive assessments. Non-English speaking subjects will not complete the Neurocognitive assessments as the psychometric properties for translated tests are either not known or not as robust.
14. Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedures. A legally authorized representative may provide consent if the potential subject lacks the capacity to provide consent themselves.

Exclusion Criteria

1. Age <18 years.
2. KPS<70
3. Past radiation or surgical therapy to the index lesion or the newly diagnosed non-index lesion(s) is exclusionary. However, up to a total of 2 prior courses of SRT treatment to previously diagnosed lesions are allowed as long as any treated lesions are were >15mm from the index lesion.
4. Patients with >4 newly diagnosed metastases on screening MRI
5. Pregnant patients.
6. Primary germ cell tumor, small cell carcinoma, or lymphoma.
7. Leptomeningeal metastasis (LMD). Note: For the purposes of exclusion, LMD is a clinical diagnosis, defined as radiologic or clinical evidence of leptomeningeal involvement with or without positive cerebrospinal fluid (CSF) cytology.
8. Prior WBRT for brain metastases.
9. Concomitant therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device.
10. Comorbid psychiatric or neurologic disease or injury impacting cognition, in the opinion of the treating physician, that might impair patient's ability to understand or comply with the requirements of the study or to provide consent
11. Subjects who, in the investigator's opinion, are unable to understand the protocol or to give informed consent, have a history of poor cooperation, noncompliance with medical treatment, or difficulty in returning for follow up care.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Surgical Resection and GammaTile Therapy	Device: Gamma Tile-Surgically Targeted Radiation Therapy (STaRT); GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile; Other Names: Carrier Tile Brachytherapy Therapy (CTBT)
Active Comparator: Surgical Resection and Stereotactic Radiation Therapy	Radiation: Stereotactic Radiation Therapy; External Beam Radiation Therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Surgical bed recurrence-free survival (SB-RFS) from the time of randomization up to 2 years post radiation.	Surgical bed control is defined as the absence of new nodular contrast enhancement in the index lesion surgical bed.	up to 2 years post-radiation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival	Survival of subjects	up to 3 years
Functional Assessment of Cancer Therapy-Brain (FACT-Br)	An assessment of quality of life (QOL)	up to 9 months
Linear Analog Scale Assessments (LASA)	An assessment of quality of life (QOL)	up to 9 months
Hopkins Verbal Learning Test (HVLT-R)	An assessment of neurocognitive status	up to 24 months
Controlled Oral Word Association Test (COWAT)	An assessment of neurocognitive status	up to 24 months
Trail Making Tests (TMT) Parts A and B	An assessment of neurocognitive status	up to 24 months
Barthel ADL	An assessment of physical functioning status	up to 24 months

Collaborators and Investigators

• Sponsor: GT Medical Technologies, Inc.
• Investigators: Principal Investigator: Jeffrey Weinberg, MD, MD Anderson Cancer Center, Houston, TX

Publications and helpful links

General Publications

• Weinberg J. Clinical Trials in Progress: ROADS Trial. Oncology (Williston Park). 2021 Aug 8;35(8):495. doi: 10.46883/ONC.2021.3508.0495.

Study record dates

Study Major Dates

• Study Start (Actual): April 6, 2021
• Primary Completion (Estimated): December 30, 2025
• Study Completion (Estimated): December 30, 2027

Study Registration Dates

• First Submitted: April 24, 2020
• First Submitted That Met QC Criteria: April 24, 2020
• First Posted (Actual): April 28, 2020

Study Record Updates

• Last Update Posted (Actual): March 13, 2024
• Last Update Submitted That Met QC Criteria: March 12, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Cancer; Brain; Metastases; Tumor; Radiation; GammaTile; New Diagnosis; Cs-131
• Additional Relevant MeSH Terms: Pathologic Processes; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neoplasms; Neoplasms by Site; Neoplastic Processes; Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasm Metastasis; Brain Neoplasms
• Other Study ID Numbers: GTM-102

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No